Protalex, Inc. (PRTX) Announces PRTX-100 Phase I Data Published in the Journal of Clinical Pharmacology
8/16/2013 10:02:27 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced publication of the Company’s Phase 1 study with PRTX-100 in healthy volunteers. This article entitled, "Safety, Pharmacokinetic, Immunogenicity, and Pharmacodynamic Responses in Healthy Volunteers Following a Single Intravenous Injection of Purified Staphylococcal Protein A,” appears in the Journal of Clinical Pharmacology, Volume 53 (9). The paper describes the first detailed examination of the pharmacokinetics, safety and pharmacologic activity of highly-purified staphylococcal protein A (SPA or PRTX-100) administered as an intravenous injection. A separate publication now in progress will detail the results of the Company’s first Phase 1b study of repeated doses in patients with active rheumatoid arthritis (RA) that was presented in November 2012 at the American College of Rheumatology’s Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by